23:21 , May 21, 2019 |  BC Extra  |  Company News

May 21 Company Quick Takes: Verily in deal with pharmas; plus Amryt-Aegerion, Prokaryotics

Verily, pharmas partner to develop clinical programs  The Verily Life Sciences LLC of Alphabet Inc. (NASDAQ:GOOG) partnered with Novartis AG (NYSE:NVS; SIX:NOVN), Otsuka Holdings Co. Ltd. (Tokyo:4578), Pfizer Inc. (NYSE:PFE) and Sanofi (Euronext:SAN; NASDAQ:SNY) to...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
18:07 , Mar 16, 2018 |  BC Week In Review  |  Company News

Amryt gets exclusive license to gene therapy platform

The University College Dublin (Dublin, Ireland) granted Amryt Pharma plc (LSE:AMYT) exclusive rights to a non-viral gene therapy platform. The technology uses High-Branched Poly (beta-amino ester) (HPAE) polymer technology to deliver gene therapies. Amryt is...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
00:38 , Apr 1, 2017 |  BC Extra  |  Company News

Management tracks

Immuno-oncology company Forty Seven Inc. (Palo Alto, Calif.) named Mark McCamish CEO, effective May 1. He was global head of biopharmaceutical development at the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN). Founding CEO Jonathan MacQuitty...
13:15 , Mar 9, 2017 |  BC Week In Review  |  Clinical News

Episalvan: Ph III EASE start

This month, Amryt will begin the double-blind, placebo-controlled, international Phase III EASE trial to evaluate topical Episalvan for 90 days in about 164 patients. Episalvan is approved in the EU to treat partial-thickness wounds. Amryt...
20:26 , Dec 16, 2016 |  BC Week In Review  |  Financial News

Amryt financial update

Amryt secured a €20 million ($21.1 million) credit facility with European Investment Bank . The five-year loan bears interest at 3% plus EURIBOR. Amryt Pharma plc (LSE:AMYT; ISE:AYP), Dublin, Ireland ...
17:15 , Dec 9, 2016 |  BC Week In Review  |  Company News

Amryt, Aegerion deal

Aegerion granted Amryt exclusive rights to market Lojuxta lomitapide in the European Economic Area (EEA), Middle East and North Africa (MENA), Israel and Turkey. Aegerion is eligible for milestone payments, plus royalties. Amryt will be...
07:00 , Sep 23, 2016 |  BC Extra  |  Company News

Management tracks

Zambon Co. S.p.A. (Milan, Italy), which develops CNS, respiratory and pain therapies, named Roberto Tascione CEO. He was president and CEO for Italy at Bristol-Myers Squibb Co. (NYSE:BMY). Generics company Endo International plc (NASDAQ:ENDP; TSX:ENL)...